List of Excipients in Branded Drug VIGADRONE

Generic Drugs Containing VIGADRONE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	CELLULOSE, MICROCRYSTALLINE
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	HYPROMELLOSE
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	ISOPROPYL ALCOHOL
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	POLYETHYLENE GLYCOL
Upsher-Smith Laboratories LLC	vigabatrin	0245-6001	POVIDONE

What are the Most Frequently-Used Excipients in VIGADRONE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	ISOPROPYL ALCOHOL
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	POVIDONE

Vigadrone Excipient Strategy and Commercial Opportunities in Vigabatrin

Last updated: August 22, 2026

Vigadrone is a vigabatrin product used for infantile spasms and refractory complex partial seizures. Its commercial opportunity is driven less by active-ingredient patents and more by formulation quality, pediatric usability, supply reliability, regulatory compliance, and access to the restricted distribution system. The strongest excipient strategy is a low-risk, pharmacopeial formulation that supports dose uniformity, tablet robustness, dissolution, and pediatric administration without introducing avoidable safety or bioequivalence issues.

What is Vigadrone and how is it used?

Vigadrone contains vigabatrin, an irreversible inhibitor of gamma-aminobutyric acid transaminase. In the United States, vigabatrin products are used for:

• Infantile spasms in pediatric patients one month to two years of age.
• Refractory complex partial seizures in adults and pediatric patients who have responded inadequately to several prior treatments.

Vigabatrin is administered orally. The product category includes 500 mg tablets and powder for oral solution. Pediatric dosing for infantile spasms creates a stronger commercial rationale for flexible dosage forms than the adult seizure indication alone.

The principal clinical constraint is permanent vision loss associated with vigabatrin. FDA requires the SABRIL REMS for vigabatrin products, including enrollment, ophthalmic monitoring, and controlled distribution requirements. A new Vigadrone formulation must fit within this risk-management framework rather than compete only on tablet price.[1]

What excipients are used in Vigadrone tablets?

Public labeling for vigabatrin tablets identifies a conventional solid oral excipient system. The listed excipients include:

Excipient function	Common Vigadrone tablet excipients
Diluent and compression aid	Microcrystalline cellulose
Superdisintegrant	Croscarmellose sodium
Lubricant	Magnesium stearate
Glidant	Colloidal silicon dioxide
Film-forming polymer	Hypromellose
Coating plasticizer or carrier	Polyethylene glycol
Coating pigment and opacifier	Titanium dioxide
Coating filler or anti-tacking agent	Talc

The formulation is consistent with a conventional immediate-release film-coated tablet. It does not depend on a novel delivery technology, modified-release matrix, lipid system, or complex solubilization platform.

The formulation strategy has four likely objectives:

1. Maintain rapid and reproducible release.
2. Provide adequate tablet strength during packaging and distribution.
3. Control powder adhesion and segregation during manufacturing.
4. Produce a visually consistent tablet that supports product identification.

Because vigabatrin is administered at relatively high doses, excipient selection must preserve tablet manufacturability. A high drug load can limit the amount of filler, disintegrant, and flow aid available in the formulation. Direct compression may be feasible, but roller compaction or wet granulation could provide better content uniformity and flow depending on the active pharmaceutical ingredient's particle-size distribution and morphology.

What excipient strategy best supports Vigadrone commercial differentiation?

The strongest strategy is a platform approach with a conservative tablet core and differentiated pediatric presentation.

Tablet-core strategy

A commercial Vigadrone tablet should prioritize:

• Low tablet weight relative to the 500 mg active dose.
• Rapid disintegration and dissolution.
• Low friability.
• Strong content uniformity.
• Compatibility with high-speed compression.
• Minimal sensitivity to humidity.
• Avoidance of excipients with known pediatric tolerability concerns.

Microcrystalline cellulose and croscarmellose sodium are practical choices for a high-dose immediate-release tablet. Colloidal silicon dioxide can improve flow, while magnesium stearate requires controlled blending because over-lubrication can reduce tablet hardness or slow dissolution.

The development team should evaluate:

• Magnesium stearate concentration and blending time.
• Drug particle-size distribution.
• Granule density and compressibility.
• Tablet hardness after accelerated stability.
• Dissolution across pH conditions.
• Moisture uptake and packaging performance.
• Compatibility with automated bottle or blister filling.

Coating strategy

The film coat should improve handling and identification without materially delaying disintegration. A thin hypromellose-based coat is commercially familiar. A titanium-dioxide-free coating could be considered for jurisdictions that restrict or discourage titanium dioxide, but the change would require comparative stability, appearance, and regulatory work.

Color differentiation is important because vigabatrin products are subject to controlled distribution and specialized dispensing. A distinctive color or imprint can reduce dispensing errors, particularly where multiple antiepileptic products are stored together.

Pediatric strategy

The major unmet formulation opportunity is not a more sophisticated tablet. It is a reliable pediatric dosage form.

Potential approaches include:

• Powder for oral solution in unit-dose sachets.
• A dispersible tablet.
• A tablet that can be dissolved in a defined volume of water.
• A low-volume oral suspension prepared by pharmacists or caregivers.
• A scored tablet for dose flexibility, if mechanical and stability data support the design.

The product must support the small and changing doses used in infantile spasms. Dose measurement errors are a material risk. A unit-dose powder or validated dispersible product could improve administration compared with tablet splitting or ad hoc manipulation.

Any pediatric formulation must address:

• Dose uniformity after dispersion.
• Sedimentation and redispersibility.
• Palatability.
• Microbial control.
• In-use stability.
• Device accuracy.
• Compatibility with feeding tubes.
• Caregiver instructions.
• Residual drug in cups, syringes, or bottles.

The most defensible excipient differentiation would use a limited number of well-characterized excipients and avoid unnecessary flavors, preservatives, sweeteners, or surfactants.

What formulations are commercially attractive for Vigadrone?

500 mg immediate-release tablet

The tablet remains the lowest-risk commercial platform for adult and older pediatric patients. The opportunity is primarily cost leadership, supply reliability, packaging, and distribution reach.

A differentiated tablet could use:

• Improved tablet robustness.
• A smaller tablet footprint.
• A clear score line, if dosing and regulatory requirements permit.
• Unit-dose blister packaging.
• High-contrast imprinting.
• A film coat designed for patients with swallowing difficulty.

The tablet market is likely to be exposed to generic price competition. Excipient innovation alone would not support a material premium unless it improves adherence, administration, or safety.

Powder for oral solution

Powder for oral solution has greater commercial potential in infantile spasms. It eliminates some tablet manipulation and can support weight-based dosing. A unit-dose product could also reduce caregiver preparation variability.

Key development risks include:

• Powder flow and fill-weight control.
• Hygroscopicity.
• Sachet seal integrity.
• Reconstitution volume.
• Short in-use stability.
• Palatability.
• Packaging compatibility.
• Dose recovery from the administration vessel.

An oral solution format may command stronger clinical and commercial differentiation than a conventional tablet, but it carries more development and manufacturing complexity.

Dispersible or orally disintegrating tablet

A dispersible tablet could occupy a middle position between the tablet and powder-for-solution products. It may improve pediatric administration while retaining solid-dose manufacturing and distribution.

The main technical questions are:

• Whether a 500 mg active load can be compressed into an acceptable tablet.
• Whether the tablet disperses rapidly in a small volume.
• Whether the dispersion remains uniform during dosing.
• Whether taste masking is necessary.
• Whether the excipient package creates unacceptable osmolality or gastrointestinal effects.

Taste masking is challenging for high-dose products. A flavor system may increase formulation complexity and create regional regulatory issues. A neutral-taste formulation with a simple administration method may be more robust than a heavily flavored product.

How can excipients create patentable commercial value?

Vigabatrin is an established active ingredient. Core composition-of-matter protection is not the primary barrier. Patent value would more likely arise from a specific formulation, manufacturing process, delivery device, or use-related combination.

Potential claim areas include:

Potential claim area	Commercial relevance	Patent strength
Defined particle-size vigabatrin composition	Controls flow, dissolution, and content uniformity	Moderate if linked to measurable performance
Specific excipient ratio	May improve compression or dissolution	Weak unless unexpected technical effect is shown
Dispersible pediatric tablet	Improves administration	Moderate to strong if supported by data
Stable oral solution or reconstituted suspension	Addresses pediatric use	Moderate
Unit-dose powder packaging	Improves dosing and stability	Moderate, often vulnerable to obviousness
Taste-masked composition	Supports pediatric adherence	Moderate if sensory and pharmacokinetic benefits are demonstrated
Feeding-tube-compatible formulation	Expands administration options	Moderate
Manufacturing process with controlled granulation	Reduces variability and improves scale-up	Moderate
Device-plus-formulation combination	Supports accurate pediatric dosing	Stronger if the combination solves a documented problem

A patent directed only to replacing one conventional filler with another would face significant obviousness risk. A stronger application would link the excipient system to a measurable result, such as:

• Faster dispersion at a defined temperature.
• Improved dose recovery from an oral syringe.
• Reduced sedimentation.
• Better stability under high humidity.
• Lower tablet weight at equivalent mechanical strength.
• Improved dissolution after prolonged storage.
• Reduced variability in pediatric administration.

The applicant should separate formulation claims from process claims and device claims. This creates a broader protection strategy across composition, manufacture, and use.

What is the Orange Book status and patent exposure for Vigadrone?

FDA's Orange Book identifies approved drug products, reference products, patent listings, and applicable exclusivity information. Vigabatrin's principal commercial exposure is generic competition because the active ingredient and original product approvals date back many years.[2]

The relevant exclusivity analysis is:

Issue	Vigadrone exposure
Active-ingredient patent	Historical protection has expired
Generic competition	High
Formulation patents	Product-specific and claim-dependent
Method-of-use patents	Possible, but indication and labeling dependent
Pediatric exclusivity	Must be assessed against the relevant reference product and FDA listing
REMS requirement	Material market-access obligation
Paragraph IV risk	Relevant for any listed formulation or method patent
Biosimilar risk	Not applicable because vigabatrin is a small molecule
Orange Book status	Must be reviewed by product, dosage form, and listed patent

A Paragraph IV challenge would be most relevant if a branded or follow-on vigabatrin product listed an unexpired formulation, method, or device patent. For an established generic tablet, the more likely competitive pathway is an ANDA relying on the reference product's safety and efficacy findings.

No biosimilar pathway applies. Vigabatrin is a chemically synthesized small molecule, so competitors use the generic-drug framework rather than the biologics license application or biosimilar pathway.

When does Vigadrone lose exclusivity?

Vigadrone's commercial exclusivity is not determined by a single expiration date. It depends on the specific patent listings, FDA exclusivity codes, dosage form, and formulation claims associated with the relevant reference product.

For the established vigabatrin market, the practical loss of exclusivity has already occurred at the active-ingredient level. Current barriers are more likely to involve:

• FDA approval and labeling requirements.
• SABRIL REMS participation.
• Manufacturing capacity.
• Controlled distribution enrollment.
• Pediatric evidence and dosage-form usability.
• Formulation-specific patents.
• Contracting and payer access.

A company seeking to launch a new vigabatrin product should distinguish between freedom to sell a conventional generic tablet and freedom to sell a differentiated pediatric formulation. The first may have limited patent exposure. The second could create new patent rights but also require additional clinical, CMC, and regulatory work.

What generic entry risks exist for Vigadrone?

The main generic-entry risks are commercial rather than molecule-patent risks.

Price erosion

Several manufacturers can compete on a conventional 500 mg tablet. Payers and specialty distributors may treat the product as therapeutically interchangeable, limiting pricing power.

REMS infrastructure

A competitor must operate within the vigabatrin risk-management system. This can increase launch costs, delay onboarding, and reduce the number of capable entrants.

Pediatric substitution limits

A powder, dispersible tablet, or oral solution may not be fully interchangeable with a conventional tablet. The dosage form can support differentiation, but it may also limit automatic substitution and increase regulatory complexity.

Supply-chain concentration

Vigabatrin manufacturing requires reliable API sourcing, controlled analytical methods, and stable packaging. A shortage or manufacturing interruption could create commercial opportunity for a supplier with redundant API and finished-dose capacity.

Label and administration risk

Products used in infantile spasms face heightened scrutiny of dose preparation and caregiver instructions. A formulation that is technically bioequivalent but difficult to administer may perform poorly in the market.

Which companies are challenging or competing with Vigadrone?

The competitive field includes:

• The originator vigabatrin product, Sabril.
• Generic vigabatrin tablet manufacturers.
• Generic vigabatrin powder-for-solution manufacturers.
• Specialty-distribution providers supporting restricted access.
• Potential developers of pediatric dispersible or liquid formulations.

The relevant competitors are not limited to companies with the same brand name. A generic manufacturer with a lower-cost tablet can pressure Vigadrone pricing, while a pediatric formulation developer can compete through administration convenience and caregiver usability.

The most attractive competitive position would combine:

1. A low-cost 500 mg tablet.
2. A pediatric powder or dispersible product.
3. Reliable enrollment and operational support for the REMS.
4. Unit-dose packaging.
5. A formulation patent with measurable performance advantages.

What licensing opportunities exist for Vigadrone excipients and delivery systems?

Licensing opportunities are strongest in three areas.

Pediatric delivery

A company with a validated dispersible tablet, oral syringe system, or unit-dose powder platform could license the technology to a vigabatrin manufacturer. The value would depend on reduced dosing error, improved dose recovery, and successful pediatric usability data.

Manufacturing technology

High-load tablet compression, continuous manufacturing, or moisture-protective packaging could reduce cost and improve supply resilience. A process license may be more practical than a formulation license if the product's excipient profile is already well established.

Market-access infrastructure

A partner with experience in restricted-distribution products could provide REMS operations, specialty pharmacy contracting, patient enrollment, and caregiver support. This is a commercial capability rather than an excipient asset, but it may determine whether a differentiated formulation reaches patients efficiently.

How strong is the patent estate for a new Vigadrone formulation?

A new vigabatrin formulation would likely have a moderate patent opportunity but a weak composition-of-matter position.

Patent strength would improve if the product has:

• A defined excipient range.
• A clear technical problem and measurable solution.
• Comparative data against tablets or existing powder products.
• Pediatric dosing advantages.
• Improved stability or administration performance.
• A device component that is difficult to design around.
• Claims covering both composition and manufacturing.

Patent strength would decline if the application relies on:

• Routine excipient substitution.
• Broad claims covering all oral vigabatrin products.
• Conventional taste masking without comparative data.
• A formulation that is indistinguishable from existing products.
• A dosing method already present in approved labeling.

A formulation patent should be paired with regulatory exclusivity planning. Patent protection alone may not prevent an ANDA applicant from entering if the applicant can carve out a protected method of use or use a non-infringing dosage form.

What commercial strategy offers the highest return?

The strongest opportunity is a pediatric-focused product rather than another undifferentiated 500 mg tablet.

A practical development sequence is:

1. Maintain a conventional immediate-release tablet as the low-risk base product.
2. Develop a unit-dose powder or dispersible dosage form for infantile spasms.
3. Use a simple excipient system with low pediatric risk.
4. Validate dosing with oral syringes and feeding tubes.
5. Build stability data around real-world administration conditions.
6. Seek formulation, process, and device patent coverage.
7. Integrate the product into the existing REMS and specialty-pharmacy system.
8. Use supply reliability and caregiver usability as commercial differentiators.

Revenue exposure is concentrated in the infantile-spasms indication because treatment begins early, dosing is weight-based, and caregivers must administer therapy repeatedly. Adult refractory seizure treatment supports volume but is more exposed to generic substitution and price competition.

Key Takeaways

• Vigadrone is a vigabatrin product competing in an established generic small-molecule market.
• The core tablet excipient system is conventional and optimized for immediate release, compression, and coating.
• The strongest commercial opportunity is a pediatric dosage form, especially a unit-dose powder, dispersible tablet, or validated oral-solution platform.
• Vigabatrin does not present a biosimilar market; competition follows the ANDA generic pathway.
• The main market barriers are REMS operations, pediatric administration, manufacturing reliability, and payer access.
• Excipient patents are strongest when tied to measurable performance improvements rather than routine substitution.
• A dual strategy combining a low-cost tablet with a differentiated pediatric product offers the clearest path to defensible commercial value.

FAQs About Vigadrone Excipient and Commercial Strategy

Can Vigadrone be reformulated as an oral liquid?

Yes. A liquid or reconstituted suspension is technically feasible, but the formulation must establish dose uniformity, stability, microbial control, palatability, and accurate administration through oral syringes or feeding tubes.

Which excipients should be avoided in a pediatric vigabatrin product?

The formulation should minimize unnecessary preservatives, surfactants, high-intensity flavors, and excipients with avoidable pediatric tolerability concerns. The final selection depends on stability, dose volume, and regional regulatory requirements.

Can a new Vigadrone formulation receive three-year FDA exclusivity?

Potentially, if it qualifies as a new drug application-supported formulation with required new clinical investigations. The eligibility depends on FDA's determination and the nature of the supporting studies.

Is a dispersible vigabatrin tablet automatically substitutable for Vigadrone tablets?

No. Substitutability depends on FDA approval, therapeutic-equivalence determinations, dosage form, labeling, and state pharmacy law. A dispersible product may require a separate regulatory and commercial positioning strategy.

Does a vigabatrin formulation patent prevent all generic competition?

No. A formulation patent may cover only a defined composition, manufacturing process, device, or use. A competitor could seek approval with a different formulation or carve out a patented method of use, subject to applicable FDA and patent requirements.

References

1. U.S. Food and Drug Administration. (2024). Sabril (vigabatrin) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2024). Vigabatrin risk evaluation and mitigation strategy. FDA.
4. DailyMed. (2024). Vigabatrin tablets prescribing information. National Library of Medicine.
5. U.S. Food and Drug Administration. (2024). Approved drug product labeling for Vigadrone (vigabatrin). FDA.